Stay updated with breaking news from Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Artia Global Partners LP raised its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 422.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 824,363 shares of the company’s stock after acquiring an additional 666,600 shares during the […]
Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $16.00 to $15.00 in a report issued on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts also recently weighed in on ROIV. Truist Financial reissued a buy rating and […]
Roivant Sciences (NASDAQ:ROIV – Get Free Report) and LifeVantage (NASDAQ:LFVN – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk. Risk and Volatility Roivant Sciences has a beta of […]
Immunovant (NASDAQ:IMVT – Free Report) had its target price hoisted by HC Wainwright from $29.00 to $47.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, FY2024 […]
Immunovant (NASDAQ:IMVT – Free Report) had its price target boosted by HC Wainwright from $29.00 to $47.00 in a research report released on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, […]